Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Sehgal completed his fellowship training in hematology and medical oncology at Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital, in 2020. Prior to this, he earned his medical degree from the All India Institute of Medical Sciences, New Delhi, and finished residency training in internal medicine at Yale-New Haven Hospital, CT. Dr. Sehgal's research interests are in the fields of translational immuno-oncology and experimental therapeutics. He has previously trained in the Dhodapkar Laboratory at Yale University and Barbie Laboratory at Dana-Farber Cancer Institute. His research has led to publications in scientific journals such as Science Translational Medicine, Nature Medicine, Blood and Journal of Immunology. He is currently engaged in clinical and translational research directed towards delineating mechanisms of therapeutic resistance to immune checkpoint inhibitors and developing more effective combinations with molecularly targeted therapies.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions